Table 3.
Comparisons with the greatest differences (positive or negative) in post-progression survival (n=25)
| Comparisons showing a benefit in OS with the biologic/targeted therapy | |||||||
| Reference | Disease site | Line of therapy | Comparison (n) | Median OS (months) | Median PFS (months) | Delta PPS between arms | Study quality |
| Rule et al. 201677 | Mantle cell lymphoma | 1 | fludarabine + cyclophosphamide + rituximab (n=186) | 44.5 | 29.8 | -7.4 | 6 |
| fludarabine + cyclophosphamide (n=184) | 37 | 14.9 | |||||
| Wu et al. 201577 | NSCLC | 1 | erlotinib (n=110) | 26.3 | 11.0 | -4.7 | 8 |
| gemcitabine + cisplatin (n=107) | 25.5 | 5.5 | |||||
| Chinot et al. 201478 | Glioblastoma | 1 | temozolomide + bevacizumab (n=458) | 16.8 | 10.6 | -4.3 | 10 |
| temozolomide + placebo (n=463) | 16.7 | 6.2 | |||||
| Schwartzberg et al. 201079 | Breast | 1 | lapatinib + letrozole (n=111) | 33.3 | 8.2 | -4.2 | 10 |
| placebo + letrozole (n=108) | 32.3 | 3.0 | |||||
| Krop et al. 201780 | Breast | 3+ | trastuzumab (n=404) | 22.7 | 6.2 | 4.0 | 8 |
| physician choice (n=198) | 15.8 | 3.3 | |||||
| Sanborn et al. 201713 | SCLC | 1 | platinum + etoposide + vandetanib (n=34) | 13.2 | 5.6 | 4.1 | 8 |
| platinum + etoposide + placebo (n=33) | 9.2 | 5.7 | |||||
| Guan et al. 201381 | Breast | 1 | lapatinib + paclitaxel (n=222) | 27.8 | 9.7 | 4.1 | 10 |
| placebo + paclitaxel (n=222) | 20.5 | 6.5 | |||||
| Herbst et al. 201662 | NSCLC | 2+ | Pembrolizumab 10mg/kg (n=346) | 12.7 | 4 | 4.2 | 7 |
| docetaxel (n=343) | 8.5 | 4 | |||||
| Borghaei et al. 201557 | NSCLC | 2 | nivolumab (n=292) | 12.2 | 2.3 | 4.7 | 6 |
| docetaxel (n=290) | 9.4 | 4.2 | |||||
| Lee et al. 201364 | NSCLC | 2 | erlotinib (n=82) | 22.8 | 3.8 | 5.7 | 7 |
| pemetrexed (n=80) | 17.7 | 4.4 | |||||
| Han et al. 201761 | NSCLC | 1 | gefitinib (n=41) | 25.8 | 5.7 | 7.7 | 7 |
| pemetrexed + carboplatin (n=40) | 24.3 | 11.9 | |||||
| NCT0044827967 | Breast | 2 | chemotherapy + trastuzumab (n=29) | 26.7 | 9.4 | 7.9 | 4 |
| chemotherapy (n=29) | 19.1 | 9.7 | |||||
| Tap et al. 20165 | Sarcoma | 1+ | olaratumab + doxorubicin (n=66) | 26.5 | 6.6 | 9.3 | 7 |
| doxorubicin (n=67) | 14.7 | 4.1 | |||||
| Jonasch et al. 201763 | Renal cell | 2+ | MK-2206 (n=29) | 23.5 | 3.7 | 10.1 | 5 |
| everolimus (n=14) | 15.7 | 6.0 | |||||
| Furtado et al. 201582 | Mantle cell lymphoma | 2 | cyclophosphamide + doxorubicin + vincristine + bortezomib (n=23) | 35.6 | 16.5 | 15.4 | 5 |
| cyclophosphamide + doxorubicin + vincristine (n=23) | 11.8 | 8.1 | |||||
| Harrington et al. 201383 | SCCHN | 1 | lapatinib + cisplatin (n=34) | 48.4 | 20.4 | 17.1 | 10 |
| placebo + cisplatin (n=33) | 23.0 | 12.1 | |||||
| Comparisons showing no benefit in OS with the biologic/targeted therapy | |||||||
| Vergote, et al. 201450 | Ovarian | Maintenance | erlotinib (n=420) | 50.8 | 12.7 | -8.6 | 7 |
| no treatment (n=415) | 59.1 | 12.4 | |||||
| Shaw et al. 201348 | NSCLC | 2 | crizotinib (n=173) | 20.3 | 7.7 | -7.2 | 8 |
| pemetrexed or docetaxel (n=174) | 22.8 | 3.0 | |||||
| NCT0077717942 | NSCLC | Maintenance | vandetanib (n=75) | 15.6 | 2.7 | -6.2 | 7 |
| placebo (n=42) | 20.8 | 1.7 | |||||
| Mok et al. 201784 | NSCLC | 2 | gefitinib + chemotherapy (n=133) | 13.4 | 5.4 | -6.1 | 10 |
| placebo + chemotherapy (n=132) | 19.5 | 5.4 | |||||
| Wu et al. 201453 | NSCLC | 1 | afatinib (n=242) | 23.1 | 11.0 | -5.8 | 7 |
| gemcitabine + cislatin (n=122) | 23.5 | 5.6 | |||||
| Hegewisch-Becker et al. 201515 | Colorectal | Maintenance | fluoropyrimidine + bevacizumab (n=158) | 20.2 | 6.3 | -5.7 | 7 |
| no maintenance (n=158) | 23.1 | 3.5 | |||||
| Martin et al. 201532 | Breast | 1 | letrozole or fulvestrant + bevacizumab (n=191) | 52.1 | 19.3 | -5.6 | 6 |
| letrozole or fulvestrant (n=189) | 52.8 | 14.4 | |||||
| Vincent et al. 201751 | Colorectal | 1 | erlotinib + capecitabine (n=42) | 12.4 | 9.2 | -5.1 | 7 |
| capecitabine (n=40) | 16.2 | 7.9 | |||||
| Herrlinger et al. 201627 | Glioblastoma | 1 | bevacizumb + irinotecan (n=122) | 16.6 | 9.7 | -4.6 | 7 |
| temozolomide (n=60) | 17.5 | 6.0 | |||||